OLMA · Olema Pharmaceuticals, Inc.

Summary

Olema Pharmaceuticals, Inc. reported fourth quarter and full year 2025 financial results, with GAAP net loss of $46.1 million and $162.5 million, respectively, compared to $33.6 million and $129.5 million in 2024 periods. Ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities after $218.5 million gross proceeds from a public offering of 11,500,000 shares.